Author’s Reply
References
- Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; et al.; RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361, 1139–1151. [Google Scholar] [CrossRef] [PubMed]
- Patel, M.R.; Mahaffey, K.W.; Garg, J.; Pan, G.; Singer, D.E.; Hacke, W.; et al.; ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365, 883–891. [Google Scholar] [CrossRef] [PubMed]
© 2017 by the author. Attribution - Non-Commercial - NoDerivatives 4.0.
Share and Cite
Nietlispach, F.; Maisano, F. Author’s Reply. Cardiovasc. Med. 2017, 20, 78. https://doi.org/10.4414/cvm.2017.00468
Nietlispach F, Maisano F. Author’s Reply. Cardiovascular Medicine. 2017; 20(3):78. https://doi.org/10.4414/cvm.2017.00468
Chicago/Turabian StyleNietlispach, Fabian, and Francesco Maisano. 2017. "Author’s Reply" Cardiovascular Medicine 20, no. 3: 78. https://doi.org/10.4414/cvm.2017.00468
APA StyleNietlispach, F., & Maisano, F. (2017). Author’s Reply. Cardiovascular Medicine, 20(3), 78. https://doi.org/10.4414/cvm.2017.00468